Association of menopausal hormone therapy with risk of cardiovascular disease in Korean women
European Journal of Endocrinology · 2025
DOI: 10.1093/ejendo/lvae161 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Endocrinology, 2025. Verfasst von Jin-Sung Yuk und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Sanggye Paik Hospital, School of Medicine, Inje University, 1342 Dongil-ro, Nowon-Gu, Seoul 01757, Republic …. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Menopause, Estrogen Replacement Therapy, Hormone Replacement Therapy. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: Basic Science Research Program, National Research Foundation of Korea, Ministry of Education.
Abstract (Originalsprache)
Objective
To evaluate the association between various regimens and combinations of menopausal hormone therapy (MHT) and the risk of cardiovascular disease (CVD) in clinical practice.
Design
This was a population-based cohort study.
Methods
This population-based cohort study used data from the Health Insurance Review and Assessment Service. The data of women who reported entering menopause at ≥40 years of age with no history of CVD in the national health examination between 2011 and 2014 were extracted. A total of 134 298 pairs were included in the MHT and non-MHT groups after 1:1 propensity score matching. The participants were followed until December, 31, 2020.
Results
During a median follow-up of 7.9 (IQR 6.9-8.9) years, the incidences of CVD were 146 per 100 000 person/year and 179 per 100 000 person/year for the non-MHT and MHT groups, respectively. After adjusting for covariates, MHT use was associated with an increased CVD risk (hazard ratio [HR], 1.22 [1.14-1.31]) compared with the non-MHT group; the risk was based on an increased risk of stroke and coronary artery revascularization. Tibolone (HR, 1.38, [1.27-1.50]) was associated with increased CVD, but estrogen alone or combined estrogen/progestogen was not. There was no difference in CVD risk, regardless of the type of estrogen agent used. For combined estrogen/progestogen therapy, dydrogesterone was associated with reduced CVD risk.
Conclusions
There was an increased risk of CVD in MHT users. By regimen, tibolone use was associated with increased risk of CVD, whereas estrogen either alone or in combination with progestogen was not. There was no difference according to the type of estrogen. The type of progestogen seems to modify the results, since dydrogesterone was associated with reduced CVD risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Sanggye Paik Hospital, School of Medicine, Inje University, 1342 Dongil-ro, Nowon-Gu, Seoul 01757, Republic of Korea.
- Division of Cardiology, Department of Internal Medicine, Sanggye Paik Hospital, Inje University College of Medicine, 1342 Dongil-ro, Nowon-Gu, Seoul 01757, Republic of Korea.
ORCID-Profile: Jin-Sung Yuk, Byung Gyu Kim
Förderung
- Basic Science Research Program
- National Research Foundation of Korea
- Ministry of Education
Zitieren
APA
Yuk, J. S., Kim, G. S., Kim, D. G., Byun, Y. S., Kim, M. H., Yoon, S. H., Han, G. H., & Kim, B. G. (2025). Association of menopausal hormone therapy with risk of cardiovascular disease in Korean women. European Journal of Endocrinology. https://doi.org/10.1093/ejendo/lvae161
Vancouver
Yuk JS, Kim GS, Kim DG, Byun YS, Kim MH, Yoon SH, et al. Association of menopausal hormone therapy with risk of cardiovascular disease in Korean women. European Journal of Endocrinology. 2025. doi:10.1093/ejendo/lvae161
BibTeX
@article{Yuk2025,
author = {Yuk, Jin-Sung and Kim, Gwang Sil and Kim, Dong-Gil and Byun, Young Sup and Kim, Myoung-Hwan and Yoon, Sang-Hee and Han, Gwan Hee and Kim, Byung Gyu},
title = {Association of menopausal hormone therapy with risk of cardiovascular disease in Korean women},
journal = {European Journal of Endocrinology},
year = {2025},
doi = {10.1093/ejendo/lvae161}
}
EUVIMED